Drug Trial Radar · NCT03228940
Safety and Effect of Oral RVX000222 in Subjects With Fabry Disease
Last checked: Nov 19, 2026Latest source record: Nov 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Nov 22, 2022
Primary completion
Nov 22, 2022
Study completion Nov 22, 2022
Sponsor
- Lead sponsor
- Resverlogix CorpIndustry
- Sponsor type
- Industry
- First posted
- Jul 25, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Fabry Disease (FD) is a rare X-linked lysosomal storage disorder (LSD) caused by mutations in the GLA gene which translates into decreased activity or lack of function of the enzyme alpha-galactosidase A (α-GAL A) and accumulation of the enzymes substrate, i.e., Gb3, throughout the body. Cardiovascular and renal complications are among the leading causes of death in FD patients. RVX000222 is a BET inhibitor which modulates the expression of a variety of genes and, due to its effects on pathways downstream of substrate accumulation and reduction of major cardiac events, holds promise as a potential add-on therapy to accompany enzyme replacement therapy (ERT) in FD patients.
Conditions
- Fabry Disease
Interventions
RVX000222Drug
oral, BID
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse eventsTime frame: 16 weeks
- Changes in clinical laboratory parametersTime frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Queen Elizabeth II Health Sciences Centre, Victoria General Site
Halifax, Nova Scotia, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.